A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

NCT07389499 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

IgA Nephropathy (IgAN)
Membranous Nephropathy
ANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN)
Refractory Podocytopathy
Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits

Interventions

BIOLOGICAL: CD19-targeted iNKT Cell Injection

Sponsor

Grit Biotechnology

Collaborators

[object Object]